ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

IMRN Immuron Ltd

2,52
-0,02 (-0,79%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Immuron Ltd IMRN NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
-0,02 -0,79% 2,52 06:00:11
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,62 2,4815 2,62 2,52 2,54
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
03.5.202412:00GLOBEImmuron Director Resignation
15.4.202412:00GLOBEImmuron to host Live Virtual Event
10.4.202412:00GLOBEImmuron Travelan® sales continued strong growth
07.3.202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.3.202412:00GLOBEImmuron Announces Positive Results Support Travelan®..
28.2.202414:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.2.202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.2.202412:00GLOBEImmuron Presentation Australian Biologics Festival 2024
13.2.202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13.2.202412:00GLOBEImmuron achieves record Travelan® sales
08.2.202412:00GLOBEImmuron CEO, Steven Lydeamore Investor Webinar Presentation
16.1.202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16.1.202412:00GLOBEImmuron achieves record half yearly Travelan® sales
22.12.202313:21EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22.12.202312:00GLOBEImmuron Clinical Trials Update
04.12.202312:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04.12.202312:00GLOBEImmuron Announces First Patients Enrolled in Campylobacter..
28.11.202312:33GLOBEImmuron CEO, Steven Lydeamore Investor Webinar Presentation
28.11.202312:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22.11.202313:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.11.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.11.202300:00GLOBEImmuron CEO Steven Lydeamore Investor Webinar Presentation
13.11.202314:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30.10.202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30.10.202312:21GLOBEImmuron CEO Steven Lydeamore presented at AusBioInvest
23.10.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.10.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.10.202312:00GLOBEImmuron Announces Travelan® Clinical Study Cohort 2..
11.10.202312:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.10.202312:00GLOBEImmuron achieves record quarterly Travelan® sales
28.9.202314:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.9.202312:18EDGAR2Form 20-F - Annual and transition report of foreign private..
13.9.202312:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13.9.202312:00GLOBEImmuron achieves record monthly Travelan® sales
11.9.202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.9.202312:00GLOBEImmuron CEO, Steven Lydeamore to present at H.C. Wainwright
30.8.202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.8.202312:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.8.202312:00GLOBEImmuron to present at the Military Health System Research..
09.8.202312:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25.7.202312:00GLOBEImmuron Announces First Patients Enrolled in Travelan®..
25.7.202303:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24.7.202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24.7.202312:00GLOBEImmuron CEO, Steven Lydeamore to present at Bioshares
11.7.202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.7.202312:00GLOBEImmuron Business Update - Ateria Health launches Juvia™ in..
05.7.202312:00GLOBEImmuron FY23 Sales increase 136% on FY22 Sales
30.6.202312:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30.6.202312:00GLOBEImmuron Chairman Transition
22.6.202312:00GLOBEImmuron Business Update: Letter to Shareholders

Kürzlich von Ihnen besucht

Delayed Upgrade Clock